


## Ruxolitinib (5 mg)

<b>Catalogue No.:</b>	PE-1856-5
<b>Description:</b>	Pharmacology: Potent and selective JAK1&2 inhibitor, IC50s=2.7, 4.5 and 322 nM for JAK1, JAK2 and JAK3 respectively (1). Blocks IL-6 signaling (IC50=281 nM) and proliferation of JAK2V617F+ Ba/F3 cells (IC50=127 nM) (2). Inhibits the proinflammatory secretome of senescent cells (3). The JAK1 S646P mutant is sensitive to ruxolitinib (4). Clinically useful anticancer agent. PubChem CID: 2512798
	Product is sold for research use only. Not for human therapeutic use or for medicinal purposes
<b>Batch No.:</b>	See product label.
<b>Unit size:</b>	5 mg
<b>Other Names:</b>	INCB018424; CAS #:941678-49-5; INCB-018424
<b>Molecular Weight:</b>	306.4 g/mol. Molecular Formula: C <sub>17</sub> H <sub>18</sub> N <sub>6</sub>
<b>Compound Name:</b>	(3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile
<b>Purity:</b>	>98% (HPLC); NMR (Conforms)
<b>Biol. activity:</b>	Ruxolitinib is an orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.
<b>Applications:</b>	Biochemical inhibition.
<b>Appearance:</b>	Dry, white powder.
<b>Reconstitution:</b>	Soluble in DMSO. May be dissolved in DMSO up to 28 mg/mL or 15 mg/mL ethanol
<b>Storage:</b>	Store desiccated as supplied at -20C for up to 2 years. Store solutions at -20C for up to 1 month. Prevent multiple freeze-thaw cycles.
<b>Expiry Date:</b>	See storage conditions.
<b>General References:</b>	<ol style="list-style-type: none"><li>1. S Verstovsek et al. Hematol. Am. Soc. Hematol. Educ. Program 2009 2009(1)636</li><li>2. A Quintas-Cardama et al. Blood 2010 115:3109</li><li>3. JN Farr et al. Nat. Med. 2017 23:1072</li><li>4. Q Li et al. Oncotarget 2017 8:34687</li></ol>

---

FOR RESEARCH USE ONLY

## Ruxolitinib (5 mg)



biosensis

---

FOR RESEARCH USE ONLY